Orthofix Medical Files 8-K, Confirms Nasdaq Listing
Ticker: OFIX · Form: 8-K · Filed: Jan 8, 2024 · CIK: 884624
Complexity: simple
Sentiment: neutral
Topics: regulatory-filing, corporate-governance
TL;DR
**OFIX filed a routine 8-K confirming its Nasdaq listing, no major news.**
AI Summary
Orthofix Medical Inc. filed an 8-K on January 8, 2024, to report a current event. This filing indicates that the company's common stock, with a $0.10 par value per share, is registered on the Nasdaq Global Select Market under the trading symbol OFIX. This matters to investors because it confirms the company's continued compliance with SEC regulations and its listing on a major stock exchange, providing liquidity and transparency for shareholders.
Why It Matters
This filing confirms Orthofix Medical's ongoing compliance with SEC reporting requirements and its active listing on the Nasdaq Global Select Market, which is crucial for investor confidence and stock liquidity.
Risk Assessment
Risk Level: low — This 8-K is a routine filing with no new material information that would significantly alter the company's risk profile.
Analyst Insight
This filing is routine and does not present new information that would warrant immediate action. Investors should continue to monitor for more substantive filings or news.
Key Numbers
- $0.10 — par value per share (the stated value of each common stock share)
Key Players & Entities
- Orthofix Medical Inc. (company) — the registrant filing the 8-K
- Nasdaq Global Select Market (company) — the exchange where Orthofix Medical's stock is registered
- $0.10 (dollar_amount) — par value per share of common stock
- January 8, 2024 (date) — date of earliest event reported and filing date
FAQ
What is the purpose of Orthofix Medical Inc.'s 8-K filing dated January 8, 2024?
The 8-K filing by Orthofix Medical Inc. on January 8, 2024, is a Current Report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, indicating a report of an earliest event on that date.
On which stock exchange is Orthofix Medical Inc.'s common stock registered, and what is its trading symbol?
Orthofix Medical Inc.'s common stock, with a $0.10 par value per share, is registered on the Nasdaq Global Select Market under the trading symbol OFIX.
What is the par value of Orthofix Medical Inc.'s common stock as stated in the filing?
The par value of Orthofix Medical Inc.'s common stock is $0.10 per share, as stated in the filing under 'Title of each class'.
What is the business address and phone number of Orthofix Medical Inc. according to the filing?
According to the filing, Orthofix Medical Inc.'s business address is 3451 Plano Parkway, Lewisville, Texas, 75056, and its telephone number is (214) 937-2000.
Is Orthofix Medical Inc. considered an emerging growth company based on this 8-K filing?
The filing indicates that Orthofix Medical Inc. is NOT checking the box for being an emerging growth company, meaning it does not consider itself one as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Filing Stats: 485 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-01-08 16:06:22
Key Financial Figures
- $0.10 — nge on which registered Common stock, $0.10 par value per share OFIX Nasdaq Glo
Filing Documents
- ofix-20240108.htm (8-K) — 36KB
- ofix-ex99_1.htm (EX-99.1) — 22KB
- img236010591_0.jpg (GRAPHIC) — 6KB
- 0000950170-24-002924.txt ( ) — 179KB
- ofix-20240108.xsd (EX-101.SCH) — 23KB
- ofix-20240108_htm.xml (XML) — 4KB
01 Regulation FD Disclosures
Item 7.01 Regulation FD Disclosures. On January 8, 2024, Orthofix Medical Inc. (the “Company”) issued a press release regarding Massimo Calafiore beginning service as the Company’s President and Chief Executive Officer as of such date, and Julie Andrews being appointed as the Company’s incoming Chief Financial Officer. The information furnished in this Item 7.01 will not be treated as “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section. This information will not be deemed incorporated by reference into any filing under the Securities Act, or into another filing under the Exchange Act, unless that filing expressly incorporates by reference this Item 7.01 of this report.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits 99.1 Press release, dated January 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Orthofix Medical Inc. By: /s/ Geoffrey Gillespie Geoffrey Gillespie Interim Chief Financial Officer Date: January 8, 2024